Abstract Bacillus Calmette-Guérin (BCG) is the most effective intravesical immunotherapy for
superficial bladder cancer. Although generally well tolerated, BCG-related infectious …

Because of its proven efficacy, intravesical Bacillus Calmette‐Guérin (BCG) immunotherapy
is an important treatment for nonmuscle invasive bladder cancer at high risk of recurrence or …

Bladder cancer is the sixth most common cancer in the United States, and 70% of cases are
non–muscle invasive. Intravesical bacillus Calmette-Guérin (BCG) immunotherapy …

Intravesical therapy with bacillus Calmette-Guerin (BCG) has proved to be more effective in
the prophylaxis and treatment of superficial bladder tumors and carcinoma in situ than most …

Intravesical instillation of bacille Calmette-Guérin (BCG) effectively treats transitional cell
carcinoma of the bladder. Occasionally, BCG infection complicates such treatment. In some …

Bacillus Calmette–Guérin (BCG) immunotherapy for bladder cancer has been used since
1976 when the first evidence of its ability to lower recurrence and progression rates was …

Knowing when to give and when to withhold BCG will prevent most complications, but even
when all precautions are taken, some complications will occur. The initial step in the …

This paper provides recommendations on the management of complications arising from
intravesical treatment with bacillus Calmette–Guérin (BCG) for nonmuscle-invasive bladder …

Physicians treating patients affected by nonmuscle-invasive bladder cancer (NMIBC) have
been in shock during the last six years since manufacturing restrictions on the production of …

Background. Intravesical instillations with bacillus Calmette-Guérin (BCG) is considered the
treatment of choice in the prophylaxis of high-grade superficial bladder carcinoma and in the …